Buscar en
Revista Colombiana de Cardiología
Toda la web
Inicio Revista Colombiana de Cardiología Valor pronóstico de la proteína C reactiva en los pacientes con infarto agudo ...
Información de la revista
Vol. 18. Núm. 5.
Páginas 268-272 (Agosto - Octubre 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 18. Núm. 5.
Páginas 268-272 (Agosto - Octubre 2011)
DOI: 10.1016/S0120-5633(11)70197-8
Open Access
Valor pronóstico de la proteína C reactiva en los pacientes con infarto agudo del miocardio sometidos a intervencionismo coronario percutáneo
Prognostic value of C-reactive protein in patients with acute myocardial infarction undergoing percutaneous coronary intervention
Visitas
...
Clara Saldarriaga1,2,3,
Autor para correspondencia
clarais@une.net.co

Correspondencia: Clínica Cardiovascular Santa María. Calle 78B No. 75-21. Teléfono: (57-4) 4 45 40 00.
, Juan D. Ramírez3, María C. Cardona3, Gloria Franco1
1 Clínica Cardiovascular Santa María, Medellín, Colombia
2 Sección de Cardiología, Universidad de Antioquia, Medellín, Colombia
3 Universidad Pontificia Bolivariana, Medellín, Colombia
Información del artículo
Introducción

la proteína C reactiva (PCR) es un predictor de eventos cardiovasculares, cuya relación con la muerte, el reinfarto o la revascularización luego del implante de stent en pacientes con síndrome coronario agudo, es un tema de investigación actual.

Objetivo

evaluar el valor pronóstico de la proteína C reactiva (PCR) en pacientes con síndrome coronario agudo que se llevaron a intervencionismo percutáneo.

Metodología

estudio retrospectivo en el que se comparó muerte, reinfarto o revascularización en 1, 6 y 12 meses después del intervencionismo percutáneo en el grupo de PCR baja (menor a 5mg/ L) vs. PCR alta (mayor o igual a 5). Se aplicaron pruebas paramétricas para la comparación de dos medias (T de student) y Chi-cuadrado de Pearson.

Resultados

se incluyeron 103 pacientes con síndrome coronario agudo, 60,2% con infarto sin elevación del ST y 41 con infarto con elevación del ST; la edad promedio fue 65, 4±12,4 años y el valor promedio de la PCR de 7,7±8,7mg/L. No se encontraron diferencias respecto al MACE 1, 6 y 12 meses; se observó una tendencia no significativa a mayor muerte e infarto a seis meses y a revascularización e infarto a los doce meses en el grupo de PCR alta.

Conclusión

los resultados sugieren una tendencia no significativa al aumento de los desenlaces cardiovasculares adversos en los pacientes con implante de stent por síndrome coronario agudo que tenían PCR alta.

Palabras clave:
proteína C-reactiva
infarto del miocardio
pronóstico
muerte
revascularización miocárdica
Introduction

C-reactive protein (CRP) is a predictor of cardiovascular events, whose relationship with death, reinfarction or revascularization after stent implantation in patients with acute coronary syndrome, is a topic of current research.

Objective

to evaluate the prognostic value of C-reactive protein (CRP) in patients with acute coronary syndrome who underwent percutaneous coronary intervention.

Methods

retrospective study, comparing death, reinfarction or revascularization at 1, 6 and 12 months after percutaneous coronary intervention in the group of low CRP (below 5mg / L) vs. High CRP (greater than or equal to 5). Parametric tests were applied for comparing two means (Student t test) and Pearson Chi-square.

Results

we included 103 patients with acute coronary syndrome, 60.2% with myocardial infarction with non-ST-elevation and 41 with myocardial infarction with ST elevation; mean age was 65, 4±12.4 years and the average value of the PCR was 7.7±8.7mg / L. There were no differences regarding MACE 1, 6 and 12 months; we observed a nonsignificant trend toward higher death and infarction at six months and toward revascularization and myocardial infarction at twelve months in the high CRP group.

Conclusion

the results suggest a nonsignificant trend to increased adverse cardiovascular outcomes in patients with stent implantation for acute coronary syndrome who had high CRP.

Key words:
C-reactive protein
myocardial infarction
prognosis
death
myocardial revascularization
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Beltrán, M. Herrera, R. Beltrán, E. Hurtado, V. Caicedo, M. Jaramillo, et al.
Epidemiología del síndrome coronario agudo.
Rev Colomb Cardiol, 15 (2008), pp. 145-150
[2.]
R. Kornowski, M.K. Hong, F.O. Tio, O. Bramwell, H. Wu, M.B. Leon.
In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia.
J Am Coll Cardiol, 31 (1998), pp. 224-230
[3.]
R. Kornowski, M.K. Hong, J. Saucedo, L.F. Satler, A.D. Pichard, K.M. Kent, et al.
Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes.
Am J Cardiol, 82 (1998), pp. 1163-1167
[4.]
L.M. Biasucci, G. Liuzzo, R. Della Bona, M. Leo, G. Biasillo, D.J. Angiolillo, et al.
Different apparent prognostic value of hsCRP in type 2 diabetic and nondiabetic patients with acute coronary syndromes.
Clin Chem, 55 (2009), pp. 365-368
[5.]
P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, N.R. Cook.
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
N Engl J Med, 347 (2002), pp. 1557-1561
[6.]
Y. Zhao, R. Wang, X. Ma, X. Yan, Z. Zhang, X. He, J. He.
Distribution of C-reactive protein and its association with cardiovascular risk factors in a population-based sample of Chinese.
Dis Markers, 28 (2010), pp. 333-342
[7.]
R.A. Montone, G. Ferrante, M. Bacà, G. Niccoli.
Predictive value of C-reactive protein after drug-eluting stent implantation.
Future Cardiol, 6 (2010), pp. 167-179
[8.]
J.J. Li, Y. Ren, K.J. Chen, A.C. Yeung, B. Xu, X.M. Ruan, et al.
Impact of C-reactive protein on in-stent restenosis: a meta-analysis.
Tex Heart Inst J, 37 (2010), pp. 49-57
[9.]
E.L. Kilpatrick, D.M. Bunk.
Reference measurement procedure development for Creactive protein in human serum.
Anal Chem, 81 (2009), pp. 8610-8616
[10.]
T. Killip, J.T. Kimball.
Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.
Am J Cardiol, 20 (1967), pp. 457-464
[11.]
C. Gabay, I. Kushner.
Acute phase proteins and other systemic response to inflamation.
N Eng J Med, 340 (1999), pp. 448-454
[12.]
L.M. Biasucci, G. Liuzzo, R.L. Grillo, G. Caligiuri, A.G. Rebuzzi, A. Buffon, et al.
Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability.
Circulation, 99 (1999), pp. 855-860
[13.]
J.J. Li, G.H. Fang.
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease.
Med hypotheses, 62 (2004), pp. 499-506
[14.]
G. Niccoli, R.A. Montone, G. Ferrante, F. Crea.
The evolving role of inflammatory biomarkers in risk assessment after stent implantation.
J Am Coll Cardiol, 56 (2010), pp. 1783-1793
[15.]
J.P. Empana, X. Jouven, F. Canouï-Poitrine, G. Luc, M. Tafflet, B. Haas, et al.
Creactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: the PRIME study.
Arterioscler Thromb Vasc Biol, 30 (2010), pp. 2047-2052
[16.]
G. Ferrante, G. Niccoli, L.M. Biasucci.
Association between C reactive protein and angiographic reestenosis after bare metal stents: an update and comprehensive meta analysis of 2747 patients.
Cardiovasc Revasc Med, 9 (2008), pp. 156-165
[17.]
S. Hoshida, M. Nishino, T. Takeda, J. Tanouchi, Y. Yamada, M. Hori.
A persistent increase in C reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins.
Atherosclerosis, 173 (2004), pp. 285-290
[18.]
D.H. Walter, S. Fichtlscherer, M. Sellwig, W. Auch-Schwelk, V. Schachinger, A.M. Zeiher, C. Preprocedural.
reactive protein levels and cardiovascular events after coronary stent implantation.
J Am Coll Cardiol, 37 (2001), pp. 839-846
[19.]
A. Gaspardone, F. Versaci, F. Tomai, et al.
C reactive protein, clinical outcome and restenosis rate after implantation of different drug eluting stents.
Am J Cardiol, 97 (2006), pp. 1311-1316
[20.]
A. Dibra, J. Mehi lli, S. Braun, M. Hadamitzky, H. Braun, J. Dirschinger, H. Schulen, et al.
Association between C reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting.
Am J Med, 114 (2003), pp. 715-722
[21.]
Y.H. Hong, M.H. Jeong, S.Y. Lim, S.R. Lee, K.H. Kim, I.S. Sohn, et al.
Elevated preprocedural high sensitivity C reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting.
Circ J, 69 (2005), pp. 1477-1483
[22.]
Y.H. Hong, M.H. Jeong, S.Y. Lim, S.R. Lee, S.N. Hong, K.H. Kim, I.S. Sohn, et al.
Relation of soft plaque and elevated preprocedural high sensitivity C reactive protein levels to incidence of in-stent restenosis after successful coronary artery stenting.
Am J Cardiol, 98 (2006), pp. 341-345
[23.]
P. Libby, F. Crea.
Clinical implications of inflammation for cardiovascular primary prevention.
Eur Heart J, 31 (2010), pp. 777-778
[24.]
Y. Momiyama, R. Ohmori, Z.A. Fayad, T. Kihara, N. Tanaka, R. Kato, et al.
Associations between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis.
J Atheroscler Thromb, 17 (2010), pp. 460-467
[25.]
N. Rodondi, P. Marques-Vidal, J. Butler, K. Sutton-Tyrrell, J. Cornuz, S. Satterfield, et al.
Body Composition Study.
Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. Am J Epidemiol, 171 (2010), pp. 540-549
[26.]
G. Patti, V. Pasceri, G. Colonna, M. Miglionico, D. Fischetti, G. Sardella, et al.
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
J Am Coll Cardiol, 49 (2007), pp. 1272-1278
[27.]
P.W. Serruys, P. de Feyter, C. Macaya, N. Kokott, J. Puel, M. Vrolix, et al.
Lescol Intervention Prevention Study(LIPS) Investigators Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a controlled trial.
JAMA, 287 (2002), pp. 3215-3222
Copyright © 2011. Sociedad Colombiana de Cardiología y Cirugía Cardiovascular
Opciones de artículo
Herramientas
es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.